DN022150
/ Shanghai De Novo Pharmatech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 21, 2025
Phase I/IIa Study evaluating the safety, tolerability, pharmacokinetics, and efficacy of DN022150 in patients with advanced solid tumors Harboring KRASG12D mutation
(ChiCTR)
- P1/2 | N=181 | Recruiting | Sponsor: Zhongshan Hospital ,Fudan University; Zhongshan Hospital ,Fudan University | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor • KRAS
November 10, 2024
Phase I/IIa Study evaluating the safety, tolerability, pharmacokinetics, and efficacy of DN022150 in patients with advanced solid tumors Harboring KRASG12D mutation
(ChiCTR)
- P1/2 | N=181 | Not yet recruiting | Sponsor: Zhongshan Hospital ,Fudan University; Zhongshan Hospital ,Fudan University
Metastases • New P1/2 trial • Oncology • Solid Tumor • KRAS
1 to 2
Of
2
Go to page
1